Zymeworks Inc. (ZYME.TO)
| Previous Close | 32.57 |
| Open | 33.05 |
| Bid | 33.04 x 0 |
| Ask | 33.14 x 0 |
| Day's Range | 32.77 - 33.53 |
| 52 Week Range | 32.77 - 33.53 |
| Volume | 5,350 |
| Avg. Volume | 5,400 |
| Market Cap | 1.3B |
| Beta (5Y Monthly) | 0.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.89 |
| Earnings Date | Nov. 01, 2021 - Nov. 05, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 47.50 |
- Simply Wall St.
We're Not Worried About Zymeworks' (NYSE:ZYME) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Business Wire
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
VANCOUVER, British Columbia, September 16, 2021--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that new clinical data for zanidatamab, a HER2‑targeted bispecific antibody, demonstrate promising response rates and durability in first-line HER2-positive GEA. These data were presented today by lead study investigator, Geoffrey Ku, M.D., Medical Oncologist at Memorial Sloan Kettering Cancer Center (MSK), at the ESM
- Business Wire
Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
VANCOUVER, British Columbia, September 12, 2021--This press release announces the availability of an abstract that Zymeworks is presenting at the upcoming ESMO Congress
